Johnson & Johnson Presents New IMAAVY Data at European Neurology Congress

MT Newswires Live03:07

Johnson & Johnson (JNJ) on Friday presented new data on IMAAVY, nipocalimab-aahu, its treatment for generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness, across 12 abstracts at the European Academy of Neurology 2026 Congress.

Data from the Vivacity-MG3 trial showed patients who received IMAAVY alongside standard care early in their disease saw greater symptom reductions versus placebo at week 24 (-4.9 vs. -2.7), with more patients achieving sustained clinical improvement lasting 20 or more weeks, the company said.

Patients with less severe disease at baseline showed similar benefit (-4.5 vs. -2.3). Serious adverse events were lower in the IMAAVY arm than placebo (9% vs. 14%), according to the company.

IMAAVY is approved by the FDA and European Medicines Agency for adults and patients aged 12 and older with antibody-positive gMG, Johnson & Johnson said.

Price: 253.67, Change: +8.79, Percent Change: +3.59

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment